Sequoia Capital

About

Portfolio · 2

Decart

Decart is an AI lab building real-time world models and the ultra-optimized infrastructure to power them, enabling real-time interactive AI experiences.

Led ★ 3 rounds $425.0M committed Latest: 2026-05

Silent Communication

Visual Messaging and Call Management Mobile Solutions

1 round $5.0M committed Latest: 2007-11

Investment activity

46 portfolio exits on record.

Funds · 4

• Late-Stage — $7B Apr 2026
• Series A — $750M Oct 2025
• Seed — $200M Oct 2025
• 5 — $195M Jan 2023

Q&A

What was Sequoia Capital's most recent fundraise?

Sequoia Capital raised a $7 billion Late-Stage fund in April 2026.

What was a significant exit for Sequoia Capital in 2025?

In March 2025, Sequoia Capital saw Wiz, a cloud security platform, acquired by Google for $32 billion.

Which portfolio company did Sequoia Capital exit in May 2025?

Sequoia Capital exited Apex Security, a company focused on real-time detection and response to cyberattacks targeting AI platforms, in May 2025 when it was acquired by Tenable for $105 million.

What was a notable acquisition for Sequoia Capital in early 2026?

In February 2026, Sequoia Capital's portfolio company Pyramid Analytics, an enterprise business intelligence and data analytics software provider, was acquired by ServiceNow.

What is Sequoia Capital's investment focus by sector?

Sequoia Capital shows a strong focus on Business Software with 84 rounds, followed by Cyber Security with 55 rounds, and Fintech & Insurtech with 21 rounds.

Which stage does Sequoia Capital most frequently invest in?

Sequoia Capital has made 38 follow-on investments in B Round companies and 27 initial Seed investments, indicating a strong presence in early and growth stages.

What was Sequoia Capital's most recent Seed fundraise?

Sequoia Capital raised a $200 million Seed fund in October 2025.

What was a recent acquisition involving a Sequoia Capital portfolio company in the health tech sector?

In May 2026, Sequoia Capital's portfolio company EndoSpan, which develops stent graft systems, was acquired by Artivion for $335 million.